ArticleJournal of gastroenterology2023
Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Article in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 32 citations in OpenAlex.
- Clinical characteristics and survival outcomes for undifferentiated carcinoma with/without osteoclast-like giant cells of the pancreas.Updates in surgery · 2026Article
- Long-term survival with multidisciplinary treatment including local and systemic treatment for germline BRCA2-positive pancreatic acinar cell carcinoma.Clinical journal of gastroenterology · 2026Article
- Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities.Cancers · 2026Review
- Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer.Japanese journal of clinical oncology · 2026Article
- Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study.Journal of gastrointestinal cancer · 2026Article
- Progress and challenges in the development of advanced pancreatic cancer organoids.Journal of experimental & clinical cancer research : CR · 2026Review
- [Research progress in clinical pathology and molecular mechanisms of pancreatic adenosquamous carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- Recurrent pancreatic acinar cell carcinoma following a 7-year disease-free interval: A case report and literature review.International journal of surgery case reports · 2026Article
- Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database.JCO precision oncology · 2026Observational
- Oncological outcome of surgical resection for anaplastic carcinoma of the pancreas.Molecular and clinical oncology · 2025Article
- Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome.International journal of clinical oncology · 2025Review
- Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database.Journal of gastroenterology · 2025Article
- Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database.Journal of gastroenterology · 2025Article
- Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications.Cancer science · 2024Observational
- Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series.Cancers · 2024Article
- A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.Clinical journal of gastroenterology · 2024Article
- Article
- Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan.Endocrine · 2024Observational
- Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma.Clinical journal of gastroenterology · 2024Article
- Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma.Journal of cancer research and clinical oncology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpecial subtypes of pancreatic cancer, such as acinar cell carcinoma (ACC), adenosquamous carcinoma (ASC), and anaplastic carcinoma of the pancreas (ACP), are rare, and so data on them are limited. Using the C-CAT database, we analyzed clinical and genomic characteristics of patients with these and evaluated differences on comparison with pancreatic ductal adenocarcinoma (PDAC) patients.
methodsWe retrospectively reviewed data on 2691 patients with unresectable pancreatic cancer: ACC, ASC, ACP, and PDAC, entered into C-CAT from June 2019 to December 2021. The clinical features, MSI/TMB status, genomic alterations, overall response rate (ORR), disease control rate (DCR), and time to treatment failure (TTF) on receiving FOLFIRINOX (FFX) or GEM + nab-PTX (GnP) therapy as first-line treatment were evaluated.
resultsNumbers of patients with ACC, ASC, ACP, and PDAC were 44 (1.6%), 54 (2.0%), 25 (0.9%), and 2,568 (95.4%), respectively. KRAS and TP53 mutations were prevalent in ASC, ACP, and PDAC (90.7/85.2, 76.0/68.0, and 85.1/69.1%, respectively), while their rates were both significantly lower in ACC (13.6/15.9%, respectively). Conversely, the rate of homologous recombination-related (HRR) genes, including ATM and BRCA1/2, was significantly higher in ACC (11.4/15.9%) than PDAC (2.5/3.7%). In ASC and ACP, no significant differences in ORR, DCR, or TTF between FFX and GnP were noted, while ACC patients showed a trend toward higher ORR with FFX than GnP (61.5 vs. 23.5%, p = 0.06) and significantly more favorable TTF (median 42.3 vs. 21.0 weeks, respectively, p = 0.004).
conclusionsACC clearly harbors different genomics compared with PDAC, possibly accounting for differences in treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.